BRIEF-Olema Oncology Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate Op-3136 In Combination With Nubeqa® (Darolutamide) In Metastatic Castration-Resistant Prostate Cancer

Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc.

OLMA

0.00

May 26 (Reuters) - Olema Pharmaceuticals Inc OLMA.O:

  • OLEMA ONCOLOGY ANNOUNCES CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH BAYER TO EVALUATE OP-3136 IN COMBINATION WITH NUBEQA® (DAROLUTAMIDE) IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

  • OLEMA PHARMACEUTICALS INC - ANNOUNCES CLINICAL TRIAL COLLABORATION WITH BAYER FOR OP-3,136 AND DAROLUTAMIDE IN MCRPC

  • OLEMA PHARMACEUTICALS INC - STUDY TO EVALUATE OP-3,136 AND DAROLUTAMIDE IN 36 PATIENTS, INITIATION EXPECTED IN H2 2026

Source text: ID:nGNX4YnNbN

Further company coverage: OLMA.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.